Hsbc Holdings PLC Has $9.13 Million Stock Holdings in Guardant Health, Inc. $GH

Posted by Francis Steltz on Jul 23rd, 2026

Hsbc Holdings PLC grew its holdings in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 1,069.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 98,843 shares of the company’s stock after purchasing an additional 90,392 shares during the period. Hsbc Holdings PLC’s holdings in Guardant Health were worth $9,130,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of GH. V Square Quantitative Management LLC acquired a new stake in Guardant Health in the fourth quarter valued at about $27,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health in the fourth quarter valued at about $31,000. Elyxium Wealth LLC acquired a new position in Guardant Health during the fourth quarter worth about $35,000. Parallel Advisors LLC raised its stake in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares in the last quarter. Finally, EFG International AG acquired a new stake in shares of Guardant Health in the 4th quarter valued at approximately $41,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on GH shares. JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Royal Bank Of Canada began coverage on shares of Guardant Health in a research report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 target price on the stock. Piper Sandler set a $127.00 target price on shares of Guardant Health in a research note on Thursday, May 21st. Wolfe Research started coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target for the company. Finally, Barclays increased their price target on Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $160.04.

View Our Latest Stock Analysis on Guardant Health

Guardant Health Price Performance

NASDAQ:GH opened at $150.75 on Thursday. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08. The company has a market cap of $19.99 billion, a PE ratio of -44.47 and a beta of 1.59. The firm’s 50 day simple moving average is $137.33 and its 200 day simple moving average is $111.36.

Insider Activity

In other news, insider Chris Freeman sold 24,406 shares of Guardant Health stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the transaction, the insider owned 60,034 shares in the company, valued at approximately $7,124,234.78. The trade was a 28.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John G. Saia sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the completion of the sale, the insider directly owned 45,950 shares in the company, valued at approximately $4,894,134.50. This represents a 30.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 708,565 shares of company stock valued at $90,556,597. 5.60% of the stock is currently owned by company insiders.

About Guardant Health

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.